Elacestrant vs Vepdegestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Elacestrant

Marketed by Stemline Therapeutics, Inc. and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT03778931 · Phase 3 · completed

This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT06691035 (registry estimate)

Reported efficacy

Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)); Progression-free Survival in All Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14) (met)

Result source: NCT03778931

Vepdegestrant · Veppanu

Marketed by Rigel Pharmaceuticals and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT05654623 · Phase 3 · active, not recruiting

Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.

Next expected readout: December 2026 · NCT05909397 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)

Result source: NCT05654623

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointElacestrantVepdegestrant
PFS, median3.8 vs 1.9vs Standard of Care (SoC)n 115NCT03778931
1 other result
3.7 vs 3.6vs Fulvestrantn 313NCT05654623
1 other result
OS, median—Trial running · NCT06382948—Trial running · NCT05909397
ORR—Trial running · NCT0638294810.9% vs 3.6%vs Fulvestrantn 221NCT05654623
Clinical benefit rate—Trial running · NCT0638294834.3% vs 28.7%vs Fulvestrantn 274NCT05654623

PFS, median

Elacestrant
3.8 vs 1.9vs Standard of Care (SoC)n 115NCT03778931
1 other result
Vepdegestrant
3.7 vs 3.6vs Fulvestrantn 313NCT05654623
1 other result

OS, median

Elacestrant
—Trial running · NCT06382948
Vepdegestrant
—Trial running · NCT05909397

ORR

Elacestrant
—Trial running · NCT06382948
Vepdegestrant
10.9% vs 3.6%vs Fulvestrantn 221NCT05654623

Clinical benefit rate

Elacestrant
—Trial running · NCT06382948
Vepdegestrant
34.3% vs 28.7%vs Fulvestrantn 274NCT05654623
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Elacestrant: 3 of 4 rows · Vepdegestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricElacestrantVepdegestrant
Dropout rate
36.4%
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.8%a
NCT05549505 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—a
NCT05549505 · Phase 2 · registry result, not featured evidence
Serious AEs
12.2%
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
4%a
NCT05549505 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
nausea 35%
fatigue 19%
vomiting 19%
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
a
hot flush 24.8%
asthenia 20.8%
constipation 15.8%
NCT05549505 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Elacestrant

Overall Survival NA vs 16.95 Standard of Care (SoC) months
time to event · months
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
NA vs NA Standard of Care (SoC) months
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Vepdegestrant

ORR 10.9% (n=221) vs 3.6% (n=222) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 34.3% (n=274) vs 28.7% (n=272) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response NA vs 7.4 Fulvestrant months
time to event · months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Ki-67 Expression -71.4% (n=93) vs -72.9% (n=46) Anastrozole @ 2.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 71.4 Percent reduction as posted
Pathological Complete 1% (n=102) vs 0% (n=50) Anastrozole @ 22.57wk
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
mPEPI Score 0 20.6% (n=102) vs 20% (n=50) Anastrozole @ 22.57wk
event count · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
Breast Conserving Surgery 69.6% (n=102) vs 54% (n=50) Anastrozole
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
Stable Disease 37.3% (n=102) vs 32% (n=50) Anastrozole @ 24wk
event count · % of participants
Stable Disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
Progressive Disease 2.9% (n=102) vs 2% (n=50) Anastrozole @ 24wk
event count · % of participants
Progressive disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Tumor Size -32.35% (n=45) vs -42.88% (n=19) Anastrozole @ 20.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence

Breast Cancer

Shared mechanism: Estrogen receptor · full Breast Cancer pipeline

Elacestrant

Marketed by Stemline Therapeutics, Inc. and partners

Approved in Breast Cancersmall molecule
Partial signal

NCT03778931 · Phase 3 · completed

This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT06691035 (registry estimate)

Reported efficacy

Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)); Progression-free Survival in All Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14) (met)

Result source: NCT03778931

Vepdegestrant · Veppanu

Marketed by Rigel Pharmaceuticals and partners

Approved in Breast Cancersmall molecule
Partial signal

NCT05654623 · Phase 3 · active, not recruiting

Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.

Next expected readout: December 2026 · NCT05909397 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)

Result source: NCT05654623

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Elacestrant: 4 of 5 rows · Vepdegestrant: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricElacestrantVepdegestrant
PFS
time to event · months
3.78 vs 1.87 Standard of Care (SoC) monthsa,b
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
2.79 vs 1.91 Standard of Care (SoC) months
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.7 vs 3.6 Fulvestrant monthsa,b
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
5 vs 2.1 Fulvestrant months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Dropout rate
36.4%
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.8%c
NCT05549505 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—c
NCT05549505 · Phase 2 · registry result, not featured evidence
Serious AEs
12.2%
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
4%c
NCT05549505 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
nausea 35%
fatigue 19%
vomiting 19%
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
c
hot flush 24.8%
asthenia 20.8%
constipation 15.8%
NCT05549505 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bThe assessment timepoint is not available for both results.
  3. cPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Elacestrant

Overall Survival NA vs 16.95 Standard of Care (SoC) months
time to event · months
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
NA vs NA Standard of Care (SoC) months
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Vepdegestrant

ORR 10.9% (n=221) vs 3.6% (n=222) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 34.3% (n=274) vs 28.7% (n=272) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response NA vs 7.4 Fulvestrant months
time to event · months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Ki-67 Expression -71.4% (n=93) vs -72.9% (n=46) Anastrozole @ 2.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 71.4 Percent reduction as posted
Pathological Complete 1% (n=102) vs 0% (n=50) Anastrozole @ 22.57wk
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
mPEPI Score 0 20.6% (n=102) vs 20% (n=50) Anastrozole @ 22.57wk
event count · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
Breast Conserving Surgery 69.6% (n=102) vs 54% (n=50) Anastrozole
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
Stable Disease 37.3% (n=102) vs 32% (n=50) Anastrozole @ 24wk
event count · % of participants
Stable Disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
Progressive Disease 2.9% (n=102) vs 2% (n=50) Anastrozole @ 24wk
event count · % of participants
Progressive disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Tumor Size -32.35% (n=45) vs -42.88% (n=19) Anastrozole @ 20.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elacestrant's landscape · Vepdegestrant's landscape